Jonathan Wang is listed as an executive officer and director on 4 SEC Form D filings by 1 issuer between Feb 2017 and Sep 2017: OrbiMed Asia Partners III, L.P. (New York, NY — pooled investment fund — 2017; $540M reported sold to 97 investors).
What this means One deal on file with the SEC, filed Sep 2017. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
The issuer belongs to the sponsor group Orbimed (37 issuers, $20.2B reported sold, 2009–2026).
What this means A sponsor group is one team that sets up a new company for each deal. Orbimed has 37 companies on file and $20.2B reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 2 bankruptcy cases matching the name listed in Key records below.
What this means 2 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 4 public filings for Jonathan Wang and found 8 differences: Jonathan Wang's role changed at OrbiMed Asia Partners III, L.P.: executive officer → director; Offering amount changed between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.